|
Gastric Adenocarcinoma
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Undifferentiated carcinoma of ovary
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Adenocarcinoma of lung (disorder)
|
0.110 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of familial lung cancer.
|
29924316 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Driver gene mutations in BRAF, EGFR, ERBB2, HRAS, KRAS, MET, NRAS, PIK3CA, STK11, and ephrin receptor genes (EPHA1-8, 10 and EPHB1-4, 6) were studied for both LAC and MM, and in BAP1, CUL1, CDKN2A, and NF2 for MM.
|
26463840 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with metastatic high-grade (WHO G3) gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC) represent a heterogeneous subgroup with poor prognosis and standard platinum-etoposide chemotherapy has limited therapeutic benefit.
|
31846429 |
2020 |
|
Neuroendocrine Tumors
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SATB2 is frequently and strongly expressed by lower GI tract NETs; we have adopted it as our rectal NET marker.
|
31233624 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One of the main obstacles to improve current treatments is represented by the impermeability of the blood vessels residing within nervous tissue as well as of the new vascular net generating from the tumor, commonly referred to as blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB), respectively.
|
31137689 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Stratified by the tumour grade (WHO 2010 classification), we observed 64.0% of NET G1, 24.7% of NET G2, and 11.3% of NEC.
|
31467527 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These biomarkers include (1) peptides and growth factors; (2) DNA and RNA markers based on genomics analysis, for example, the so-called NET test, which has been developed for analyzing gene transcripts in circulating blood; (3) circulating tumor/endothelial/progenitor cells or cell-free tumor DNA, which represent minimally invasive methods that would provide additional information for monitoring treatment response and (4) improved imaging techniques with novel radiolabeled somatostatin analogs or peptides.
|
30615596 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although there is no category corresponding to NET G3 in the current classification of lung tumors, we consider that our tumors may correspond to NET G3 and identification of this subset is relevant for therapeutic management.
|
31511024 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
GEP-NET primary tumor location or secretory syndrome did not influence the risk for MetS.
|
31533348 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Areas covered: Two perspectives were evaluated based on an extensive review and rethinking of literature: (1) the current classification as an instrument to obtaining clinical and molecular insights into the context of Lung-NETs; and (2) an alternative and innovative interpretation of these tumors, proposing a tripartite separation into early aggressive primary high-grade neuroendocrine tumors (HGNET), differentiating or secondary HGNET, and indolent NET.
|
30900485 |
2019 |
|
Vital capacity
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Carcinoma, Neuroendocrine
|
0.100 |
Biomarker
|
disease |
BEFREE |
No prognostic difference was detected between NET G3 and NEC patients after 5 year DFS.
|
31422400 |
2019 |
|
Carcinoma, Neuroendocrine
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Herein, we report two cases of lung neuroendocrine carcinoma with carcinoid morphology that correspond to NET G3.
|
31511024 |
2019 |
|
Carcinoma, Neuroendocrine
|
0.100 |
Biomarker
|
disease |
BEFREE |
No PAX5 cytoplasmic staining was seen in all grades of NET in other organs, rectal WD-NET G3, and all neuroendocrine carcinoma.
|
29561272 |
2019 |
|
Carcinoma, Neuroendocrine
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, APOBEC3B is highly expressed in GEP-NETs and is a predictor of lymph node metastasis in NET G3 and NEC cases.
|
30095460 |
2019 |
|
Carcinoma, Neuroendocrine
|
0.100 |
Biomarker
|
disease |
BEFREE |
NET G3 are considered a molecularly, radiologically, and prognostically distinct entity compared to NEC and NET G1/G2.
|
31428952 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Appendiceal carcinoid (neuroendocrine tumor or NET) is a rare neuroendocrine neoplasm often found incidentally following appendectomy for appendicitis.
|
31555859 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent updates separate pancreatic neuroendocrine tumors into 2 broad categories: well-differentiated pancreatic neuroendocrine tumors (panNET) and poorly differentiated pancreatic neuroendocrine carcinoma (panNEC), and incorporates a new subcategory of "well-differentiated high-grade NET (G3)" to the well-differentiated NET category.
|
29912000 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The category of grade 3 neuroendocrine tumor (NET G3) was newly introduced in the 2017 World Health Organization (WHO 2017) classification of neuroendocrine neoplasms of the pancreas.
|
31511024 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
Biomarker
|
group |
BEFREE |
This work presents a first preclinical assessment of this state-of-the-art OV, using a panel of human neuroendocrine tumor/neuroendocrine carcinoma (NET/NEC) cell lines.
|
31280274 |
2019 |
|
Neuroendocrine Tumors
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Characteristics of 252 patients with bronchopulmonary neuroendocrine tumours treated at the Copenhagen NET Centre of Excellence.
|
31097087 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Secondary malignant neoplasm of colon and/or rectum
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
A genome-wide association study identifies single nucleotide polymorphisms associated with time-to-metastasis in colorectal cancer.
|
30738427 |
2019 |